REMARKS

This responds to the Office Action, dated October 23, 2006. Claims 114 and 126 have been amended. No claims have been canceled. No claims have been added.

Claims 114 and 126 have been amended to recite reference to the SEQ ID NOs referred to in Table 1 of the application and to clarify that these peptides are d-form peptide.

No new matter has been added.

Applicants assert that submission of a new sequence listing and/or amendments to the specification are not required in view of the amendments to claims 114 and 126.

Respectfully submitted,

/Jonathan M. Dermott/
Jonathan M. Dermott, Ph.D.
Reg. No. 48,608

Synnestvedt & Lechner LLP 2600 Aramark Tower 1101 Market Street Philadelphia, PA 19107-2950 Telephone - (215) 923-4466 Facsimile - (215) 923-2189

 $S:\M\MERRION\Patents\P26478-A\ USA\PTO\Reply\ to\ oa\ of\ 20061023.doc$